OM:PHLOG B

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Pharmacolog i Uppsala

Executive Summary

Pharmacolog i Uppsala AB (publ) develops systems and solutions for use of intravenous drugs in Sweden. More Details


Snowflake Analysis

Mediocre balance sheet and overvalued.

Share Price & News

How has Pharmacolog i Uppsala's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PHLOG B's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.2%

PHLOG B

-5.7%

SE Medical Equipment

-6.0%

SE Market


1 Year Return

-59.4%

PHLOG B

8.0%

SE Medical Equipment

6.2%

SE Market

Return vs Industry: PHLOG B underperformed the Swedish Medical Equipment industry which returned 8% over the past year.

Return vs Market: PHLOG B underperformed the Swedish Market which returned 6.2% over the past year.


Shareholder returns

PHLOG BIndustryMarket
7 Day-5.2%-5.7%-6.0%
30 Day-13.1%-5.7%-6.3%
90 Day-21.3%-0.7%1.7%
1 Year-59.4%-59.4%9.6%8.0%8.0%6.2%
3 Year-73.4%-77.9%58.3%39.9%22.4%9.3%
5 Year-51.9%-72.8%59.6%32.5%45.6%17.4%

Price Volatility Vs. Market

How volatile is Pharmacolog i Uppsala's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pharmacolog i Uppsala undervalued compared to its fair value and its price relative to the market?

3.86x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PHLOG B's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PHLOG B's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PHLOG B is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.

PE vs Market: PHLOG B is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PHLOG B's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PHLOG B is good value based on its PB Ratio (3.9x) compared to the SE Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Pharmacolog i Uppsala forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pharmacolog i Uppsala has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Pharmacolog i Uppsala performed over the past 5 years?

-17.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PHLOG B is currently unprofitable.

Growing Profit Margin: PHLOG B is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PHLOG B is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.

Accelerating Growth: Unable to compare PHLOG B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PHLOG B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.4%).


Return on Equity

High ROE: PHLOG B has a negative Return on Equity (-131.96%), as it is currently unprofitable.


Next Steps

Financial Health

How is Pharmacolog i Uppsala's financial position?


Financial Position Analysis

Short Term Liabilities: PHLOG B's short term assets (SEK11.2M) exceed its short term liabilities (SEK2.4M).

Long Term Liabilities: PHLOG B's short term assets (SEK11.2M) exceed its long term liabilities (SEK1.1M).


Debt to Equity History and Analysis

Debt Level: PHLOG B's debt to equity ratio (10.9%) is considered satisfactory.

Reducing Debt: PHLOG B's debt to equity ratio has increased from 1% to 10.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PHLOG B has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PHLOG B has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.5% each year


Next Steps

Dividend

What is Pharmacolog i Uppsala current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PHLOG B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PHLOG B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PHLOG B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PHLOG B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PHLOG B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average board tenure


CEO

Mats Högberg (56 yo)

no data

Tenure

Mr. Mats Högberg serves as the Chief Executive Officer of Pharmacolog i Uppsala AB (publ) and was its Director since 2017 until 2019. Mr. Högberg served as the Vice President of Sales & Marketing at Pharma ...


Board Members

NamePositionTenureCompensationOwnership
Ragnar Linder
Independent Director1.75yrsno datano data
Erik Hedlund
Chairman of the Board3.67yrsno datano data
Carl-Johan Spak
Independent Director1.75yrsno datano data
Olle Johansson
Directorno datano datano data

1.8yrs

Average Tenure

67yo

Average Age

Experienced Board: PHLOG B's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pharmacolog i Uppsala AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pharmacolog i Uppsala AB (publ)
  • Ticker: PHLOG B
  • Exchange: OM
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr43.267m
  • Shares outstanding: 9.92m
  • Website: https://www.pharmacolog.com

Number of Employees


Location

  • Pharmacolog i Uppsala AB (publ)
  • Ekeby bruk
  • Uppsala
  • Uppsala County
  • 752 75
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHLOG BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKJun 2015
PUPP.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDJun 2015

Biography

Pharmacolog i Uppsala AB (publ) develops systems and solutions for use of intravenous drugs in Sweden. The company offers DrugLog, a solution for reducing errors in the drug administration process; WasteLo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/28 21:08
End of Day Share Price2020/10/27 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.